Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

The Lancet Oncology(2023)

引用 1|浏览34
暂无评分
摘要
Pfizer.
更多
查看译文
关键词
recurrent endometrial cancer,paclitaxel,carboplatin,open-label
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要